Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Enveric Biosciences Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 1514.5× Enveric Biosciences Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| BIO | ENVB | |
|---|---|---|
Market Cap | $9.39B | $6.20M |
Sector | Health | Health |
52-Week High | $356.25 | $17.40 |
52-Week Low | $241.71 | $1.27 |
Enterprise Value | $9.14B | $1.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
